NASDAQ:ASND - Ascendis Pharma A/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $127.70 +3.05 (+2.45 %) (As of 05/24/2019 11:50 AM ET)Previous Close$124.65Today's Range$125.71 - $127.7052-Week Range$53.21 - $131.76Volume363 shsAverage Volume353,980 shsMarket Capitalization$5.38 billionP/E RatioN/ADividend YieldN/ABeta0.94 ProfileAnalyst RatingsChartEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Ascendis Pharma A/S, a clinical stage biopharmaceutical company, develops various prodrug therapies for unmet medical needs. The company develops TransCon human growth hormone, which is in Phase III clinical study in children to treat growth hormone deficiency; TransCon parathyroid hormone that is in Phase I clinical study for treating hypoparathyroidism; and TransCon C-type natriuretic peptide for the treatment of achondroplasia. It also has strategic collaborations with Sanofi to develop TransCon Peptides for the treatment of diabetes; and Genentech and Roche to develop TransCon anti-vascular endothelial growth factor (VEGF), a compound to support injection of anti-VEGF in ophthalmology. Ascendis Pharma A/S was founded in 2006 and is headquartered in Hellerup, Denmark. Receive ASND News and Ratings via Email Sign-up to receive the latest news and ratings for ASND and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ASND Previous Symbol CUSIPN/A CIK1612042 Webhttp://www.ascendispharma.com/ Phone45-7022-2244Debt Debt-to-Equity RatioN/A Current Ratio7.53 Quick Ratio7.53Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$12.50 million Price / Sales430.45 Cash FlowN/A Price / Cash FlowN/A Book Value$7.87 per share Price / Book16.23Profitability EPS (Most Recent Fiscal Year)($3.74) Net Income$-153,650,000.00 Net Margins-1,275.08% Return on Equity-40.86% Return on Assets-37.23%Miscellaneous Employees216 Outstanding Shares42,135,000Market Cap$5.38 billion Next Earnings Date5/30/2019 (Confirmed) OptionableOptionable Ascendis Pharma A/S (NASDAQ:ASND) Frequently Asked Questions What is Ascendis Pharma A/S's stock symbol? Ascendis Pharma A/S trades on the NASDAQ under the ticker symbol "ASND." How were Ascendis Pharma A/S's earnings last quarter? Ascendis Pharma A/S (NASDAQ:ASND) posted its quarterly earnings results on Wednesday, April, 3rd. The biotechnology company reported ($0.87) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.17) by $0.30. The biotechnology company earned $12 million during the quarter. Ascendis Pharma A/S had a negative return on equity of 40.86% and a negative net margin of 1,275.08%. View Ascendis Pharma A/S's Earnings History. When is Ascendis Pharma A/S's next earnings date? Ascendis Pharma A/S is scheduled to release their next quarterly earnings announcement on Thursday, May 30th 2019. View Earnings Estimates for Ascendis Pharma A/S. What price target have analysts set for ASND? 9 analysts have issued 12 month price targets for Ascendis Pharma A/S's shares. Their predictions range from $81.00 to $219.00. On average, they expect Ascendis Pharma A/S's stock price to reach $135.00 in the next year. This suggests a possible upside of 5.7% from the stock's current price. View Analyst Price Targets for Ascendis Pharma A/S. What is the consensus analysts' recommendation for Ascendis Pharma A/S? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ascendis Pharma A/S in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ascendis Pharma A/S. What are Wall Street analysts saying about Ascendis Pharma A/S stock? Here are some recent quotes from research analysts about Ascendis Pharma A/S stock: 1. According to Zacks Investment Research, "Ascendis Pharma A/S is a biopharmaceutical company. The company's product pipeline consist of TransCon Human Growth Hormone, TransCon Treprostinil, TransCon Insulin, TransCon Peptide and TransCon Ranibizumab, which are in different clinical stage, for the treatments of hormone deficiency, endocrinology, central nervous system disorders, infectious diseases and diabetes. Its technology includes TransCon which develop prodrug therapies. Ascendis Pharma A/S is based in Denmark. " (3/18/2019) 2. Cantor Fitzgerald analysts commented, ": We are initiating coverage of Ascendis Pharma (ASND) with an Overweight rating and 12-mo. PT of $102. Ascendis is a pro-drug platform company based in Denmark that focuses on endocrinology-based rare diseases. The company leverages its novel pro-drug platform, TransCon™ to improve & extend duration of de-risked clinical-stage drugs’s action in the body. The company has upcoming Ph3 in its lead asset TransCon hGH, for treating growth hormone, expected in 1Q. We remain confident in clinical success of TransCon hGH, which should drive a first leg of upside in 2019. We also think that investors will assign more credit to the platform, especially TransCon PTH with Ph2 data expected YE2019." (1/23/2019) Has Ascendis Pharma A/S been receiving favorable news coverage? Media stories about ASND stock have been trending positive this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ascendis Pharma A/S earned a media sentiment score of 2.3 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. Are investors shorting Ascendis Pharma A/S? Ascendis Pharma A/S saw a decline in short interest during the month of April. As of April 30th, there was short interest totalling 1,014,539 shares, a decline of 36.9% from the April 15th total of 1,608,562 shares. Based on an average daily trading volume, of 255,593 shares, the short-interest ratio is presently 4.0 days. Currently, 2.4% of the company's shares are short sold. View Ascendis Pharma A/S's Current Options Chain. Who are some of Ascendis Pharma A/S's key competitors? Some companies that are related to Ascendis Pharma A/S include BioMarin Pharmaceutical (BMRN), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), Ionis Pharmaceuticals (IONS), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), SAGE Therapeutics (SAGE), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), Beigene (BGNE), Alnylam Pharmaceuticals (ALNY), Loxo Oncology (LOXO) and Marina Biotech (MRNA). What other stocks do shareholders of Ascendis Pharma A/S own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ascendis Pharma A/S investors own include Neurocrine Biosciences (NBIX), Portola Pharmaceuticals (PTLA), Exelixis (EXEL), Incyte (INCY), AbbVie (ABBV), Abbott Laboratories (ABT), Aimmune Therapeutics (AIMT), Karyopharm Therapeutics (KPTI), Novavax (NVAX) and Sangamo Therapeutics (SGMO). Who are Ascendis Pharma A/S's key executives? Ascendis Pharma A/S's management team includes the folowing people: Mr. Michael Wolff Jensen, Chairman, Sr. VP & Chief Legal Officer (Age 48)Mr. Jan Møller Mikkelsen, Pres, CEO, Member of Exec. Board & Exec. Director (Age 59)Mr. Scott T. Smith, CFO, Sr. VP & Member of Exec. Board (Age 45)Mr. Peter Rasmussen, VP of Fin. & Principal Accounting Officer (Age 50)Ms. Lotte Sønderbjerg, Chief Admin. Officer & Sr. VP (Age 58) When did Ascendis Pharma A/S IPO? (ASND) raised $85 million in an IPO on Wednesday, January 28th 2015. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. BofA Merrill Lynch and Leerink Partners served as the underwriters for the IPO and Wells Fargo Securities was co-manager. Who are Ascendis Pharma A/S's major shareholders? Ascendis Pharma A/S's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (11.14%), Vivo Capital LLC (4.86%), Marshall Wace North America L.P. (2.76%), Artisan Partners Limited Partnership (2.68%), Westfield Capital Management Co. LP (1.63%) and OppenheimerFunds Inc. (1.01%). Which major investors are selling Ascendis Pharma A/S stock? ASND stock was sold by a variety of institutional investors in the last quarter, including First Manhattan Co., Vivo Capital LLC, Alps Advisors Inc., Morgan Stanley, BlackRock Inc., California Public Employees Retirement System, Goldman Sachs Group Inc. and Emory University. Which major investors are buying Ascendis Pharma A/S stock? ASND stock was bought by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, FMR LLC, Marshall Wace North America L.P., Victory Capital Management Inc., Schonfeld Strategic Advisors LLC, Westfield Capital Management Co. LP, FIL Ltd and Opaleye Management Inc.. How do I buy shares of Ascendis Pharma A/S? Shares of ASND can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Ascendis Pharma A/S's stock price today? One share of ASND stock can currently be purchased for approximately $127.70. How big of a company is Ascendis Pharma A/S? Ascendis Pharma A/S has a market capitalization of $5.38 billion and generates $12.50 million in revenue each year. The biotechnology company earns $-153,650,000.00 in net income (profit) each year or ($3.74) on an earnings per share basis. Ascendis Pharma A/S employs 216 workers across the globe. What is Ascendis Pharma A/S's official website? The official website for Ascendis Pharma A/S is http://www.ascendispharma.com/. How can I contact Ascendis Pharma A/S? Ascendis Pharma A/S's mailing address is TUBORG BOULEVARD 5, HELLERUP G7, 2900. The biotechnology company can be reached via phone at 45-7022-2244 or via email at [email protected] MarketBeat Community Rating for Ascendis Pharma A/S (NASDAQ ASND)Community Ranking: 2.6 out of 5 ( )Outperform Votes: 231 (Thanks for Voting!)Underperform Votes: 220 (Thanks for Voting!)Total Votes: 451MarketBeat's community ratings are surveys of what our community members think about Ascendis Pharma A/S and other stocks. Vote "Outperform" if you believe ASND will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ASND will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: What is the Dividend Aristocrat Index? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.